ezetimibe has been researched along with etc-1002 in 33 studies
| Studies (ezetimibe) | Trials (ezetimibe) | Recent Studies (post-2010) (ezetimibe) | Studies (etc-1002) | Trials (etc-1002) | Recent Studies (post-2010) (etc-1002) |
|---|---|---|---|---|---|
| 2,484 | 563 | 1,465 | 197 | 25 | 175 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (15.15) | 24.3611 |
| 2020's | 28 (84.85) | 2.80 |
| Authors | Studies |
|---|---|
| Ballantyne, CM; Catapano, AL; Norata, GD | 1 |
| Ballantyne, CM; Bilen, O | 1 |
| Ballantyne, CM; Banach, M; Hanselman, JC; Leiter, LA; Lepor, NE; Mancini, GBJ; Zhao, X | 1 |
| Hegele, RA; Tsimikas, S | 1 |
| Banach, M; Corsini, A; Ruscica, M; Sahebkar, A; Sirtori, CR | 1 |
| Khan, SU; Michos, ED | 1 |
| Ballantyne, CM; Bays, HE; Catapano, AL; Goldberg, AC; Laufs, U; Leiter, LA; MacDougall, D; Ray, KK; Stroes, ES; Zhao, X | 1 |
| Choksi, RR; Goldfaden, RF; Lewis, T; Niman, S; Rana, K; Reid, J; Sheikh-Ali, M | 1 |
| Bacalbasa, N; Bratu, OG; Crismaru, I; Diaconu, CC; Gaman, MA; Pantea Stoian, A; Stanescu, AMA | 1 |
| Angiolillo, DJ; Cao, D; Claessen, BE; Gibson, CM; Guedeney, P; Lepor, N; Mehran, R | 1 |
| Al Matrooshi, NO; Bhagavathula, AS; Clark, CCT; Rahmani, J | 2 |
| Piszczatoski, C; Powell, J | 1 |
| Banach, M; Penson, PE | 1 |
| Hanselman, JC; MacDougall, DE; Nicholls, SJ; Rubino, J; Sterling, LR | 1 |
| Suadoni, MT | 1 |
| Lekuona, I; Pintó, X | 1 |
| Lloyd-Jones, DM; Wilkins, JT | 1 |
| Catapano, AL; Pirillo, A | 1 |
| Aronow, WS; Bandyopadhyay, D; Devanabanda, AR; Ghosh, RK; Gupta, M; Mamas, M; Ray, KK; Tummala, R | 1 |
| Ballantyne, CM; Bays, HE; Louie, MJ; Ray, KK; Smart, J; Zhang, Y | 1 |
| Abdul-Rahman, T; Ahmad, S; Awuah, WA; Bandyopadhyay, D; Bukhari, SMA; Capriles, CAA; Corriero, AC; de Andrade, H; Goel, A; Gupta, R; Hajra, A; Herrera, EC; Lawrence, J; Mares, AC; Patel, N; Shah, R; Shaikh, R; Ulusan, S | 1 |
| Bray, S; Palagashvili, T; Sattar, N; Stroes, ESG; Toth, PP; Villa, G; Worth, GM | 1 |
| Agarwala, R; Bansal, M; Bordoloi, N; Chag, M; Chakraborty, R; Duell, PB; Iyengar, SS; Kalra, D; Kapoor, D; Kasliwal, R; Khan, A; Khanna, NN; Mahajan, K; Manoria, PC; Mehrotra, R; Mehta, A; Mehta, V; Melinker, RP; Mukhopadhyay, S; Muruganathan, A; Nanda, R; Narasingan, SN; Pancholia, AK; Pareek, KK; Prabhakar, D; Pradhan, A; Puri, R; Rastogi, A; Saboo, B; Sattur, GB; Sheikh, A; Shetty, S; Soumitra, K; Tiwaskar, MH; Wangnoo, SK; Wong, ND; Yusuf, J | 1 |
| Bañeras, J; Bello Mora, MC; Cordero, A; Cortez Quiroga, GA; Fácila, L; García, PB; González-Juanatey, JR; López-Rodríguez, L; Lorenzo, MC; Murillo, JR; Olmo, RF; Pamias, RF; Reyes-Santías, F; Rodríguez-Mañero, M; Romero-Menor, C; Salgado-Barreira, Á; Sánchez-Alvarez, S; Sandin, M; Seijas-Amigo, J; Valle, A | 1 |
| Becker, C; Bilitou, A; Katzmann, JL; Laufs, U | 1 |
| Altarabsheh, S; Cmolik, B; Deo, S; Elgudin, Y; Hawkins, N; McAllister, D; Pell, J; Rubelowsky, J; Ruel, M; Sattar, N; Sheikh, AM; Ueda, P | 1 |
| Baum, SJ; Bilitou, A; Gillard, KK; Louie, MJ; McQueen, RB; Nash, B; Ray, KK; Sasiela, WJ; Shah, H | 1 |
| Geiling, JA; Haxhikadrija, P; Lauer, B; Makhmudova, U; Maloku, A; Möbius-Winkler, S; Otto, S; Römer, R; Samadifar, B; Schulze, PC; Weingärtner, O | 1 |
| Huang, T; Jiao, L; Li, L; Luo, J; Ma, Y; Wang, J; Wang, T; Wang, X; Xu, R; Yang, B; Yang, H; Yang, R; Yang, Y; Zhang, X; Zhang, Y | 1 |
| Alber, H; Auer, J; Bilitou, A; Catapano, AL; Clodi, M; Diamand, F; Ebenbichler, C; Fließer-Görzer, E; Gelsinger, C; Hanusch, U; Koch, M; Ludvik, B; Maca, T; Schober, A; Sock, R; Speidl, WS; Stulnig, TM; Toplak, H; Weitgasser, R; Wienerroither, S; Wolowacz, SE; Zirlik, A | 1 |
| Albers, S; Boch, T; Michaeli, DT; Michaeli, JC; Michaeli, T | 1 |
| Corsini, A; Ferri, N; Ruscica, M; Santos, RD | 1 |
14 review(s) available for ezetimibe and etc-1002
| Article | Year |
|---|---|
New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs.
Topics: Azetidines; Benzimidazoles; Benzodiazepines; Carrier Proteins; Cholesterol, LDL; Dicarboxylic Acids; Dyslipidemias; Ezetimibe; Fatty Acids; Humans; Hypolipidemic Agents; Lipoprotein(a); Oligonucleotides; Oxazolidinones; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases | 2013 |
Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase.
Topics: Anticholesteremic Agents; ATP Citrate (pro-S)-Lyase; Cholesterol, LDL; Dicarboxylic Acids; Drug Therapy, Combination; Ezetimibe; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia | 2016 |
A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Dicarboxylic Acids; Drug Combinations; Dyslipidemias; Ezetimibe; Fatty Acids; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Randomized Controlled Trials as Topic; Receptors, LDL | 2020 |
Low-density lipoprotein cholesterol lowering treatment: the current approach.
Topics: Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Benzimidazoles; Bile Acids and Salts; Carrier Proteins; Cholesterol, LDL; Dicarboxylic Acids; Europe; Ezetimibe; Fatty Acids; Gene Expression; Guidelines as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Proprotein Convertase 9; RNA, Small Interfering | 2020 |
Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol, LDL; Cost-Benefit Analysis; Dicarboxylic Acids; Eicosapentaenoic Acid; Ezetimibe; Fatty Acids; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Male; Middle Aged; Myocardial Ischemia; PCSK9 Inhibitors; Practice Guidelines as Topic; Risk Reduction Behavior; RNA, Small Interfering; Secondary Prevention | 2020 |
Bempedoic Acid and Ezetimibe for the Treatment of Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Phase II/III trials.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dicarboxylic Acids; Drug Combinations; Ezetimibe; Fatty Acids; Humans; Hypercholesterolemia; Randomized Controlled Trials as Topic; Triglycerides | 2021 |
Bempedoic Acid: A New Tool in the Battle Against Hyperlipidemia.
Topics: Atherosclerosis; Dicarboxylic Acids; Drug Therapy, Combination; Ezetimibe; Fatty Acids; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents | 2021 |
Clinical development of bempedoic acid: phase 2 and phase 3 clinical trials.
Topics: Cholesterol, LDL; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dicarboxylic Acids; Drug Development; Drug Therapy, Combination; Ezetimibe; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Inflammation | 2021 |
New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Dicarboxylic Acids; Ezetimibe; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis.
Topics: Atherosclerosis; Cholesterol, LDL; Dicarboxylic Acids; Ezetimibe; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents | 2022 |
Lipid Lowering Therapy: An Era Beyond Statins.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2022 |
Network Meta-Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid-Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low-Density Lipoprotein Cholesterol.
Topics: Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol, LDL; Dicarboxylic Acids; Double-Blind Method; Ezetimibe; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Network Meta-Analysis; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.
Topics: Angiopoietin-Like Protein 3; Anticholesteremic Agents; Cardiovascular Diseases; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Pharmaceutical Preparations; Proprotein Convertase 9; Secondary Prevention | 2023 |
Fixed Combination for the Treatment of Dyslipidaemia.
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Treatment Outcome | 2023 |
5 trial(s) available for ezetimibe and etc-1002
| Article | Year |
|---|---|
Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
Topics: Aged; Biomarkers; Canada; Cholesterol, LDL; Dicarboxylic Acids; Double-Blind Method; Down-Regulation; Drug Therapy, Combination; Europe; Ezetimibe; Fatty Acids; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Time Factors; Treatment Outcome; United States | 2018 |
Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
Topics: Aged; Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Dicarboxylic Acids; Double-Blind Method; Down-Regulation; Drug Combinations; Ezetimibe; Fatty Acids; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Time Factors; Treatment Outcome; United States | 2020 |
Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial.
Topics: Anticholesteremic Agents; Atorvastatin; Dicarboxylic Acids; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Treatment Outcome | 2021 |
Factors Associated With Enhanced Low-Density Lipoprotein Cholesterol Lowering With Bempedoic Acid.
Topics: Anticholesteremic Agents; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Dicarboxylic Acids; Drug Therapy, Combination; Ezetimibe; Fatty Acids; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Treatment Outcome | 2022 |
Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Quality of Life; Treatment Outcome | 2023 |
14 other study(ies) available for ezetimibe and etc-1002
| Article | Year |
|---|---|
Lipid-Lowering Agents.
Topics: Antibodies, Monoclonal; Anticholesteremic Agents; Benzimidazoles; Caproates; Cholesterol, HDL; Cholesterol, LDL; Diacylglycerol O-Acyltransferase; Dicarboxylic Acids; Dyslipidemias; Ezetimibe; Fatty Acids; Genetic Therapy; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Lipoprotein(a); Oligonucleotides; RNA, Small Interfering | 2019 |
ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; ATP Citrate (pro-S)-Lyase; C-Reactive Protein; Clinical Trials as Topic; Dicarboxylic Acids; Drug Therapy, Combination; Ezetimibe; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Liver | 2019 |
Bempedoic acid and ezetimibe - better together.
Topics: Cardiovascular Diseases; Dicarboxylic Acids; Ezetimibe; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia | 2020 |
Lipid-lowering therapies: Better together.
Topics: Atorvastatin; Dicarboxylic Acids; Ezetimibe; Fatty Acids; Humans; Hypercholesterolemia | 2021 |
Comment on 'Bempedoic Acid and Ezetimibe for the Treatment of Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Phase II/III trials'.
Topics: Dicarboxylic Acids; Ezetimibe; Fatty Acids; Humans; Hypercholesterolemia | 2021 |
Authors' Reply to 'Comment on: Bempedoic Acid and Ezetimibe for the Treatment of Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials'.
Topics: Dicarboxylic Acids; Ezetimibe; Fatty Acids; Humans; Hypercholesterolemia | 2021 |
Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk.
Topics: Cardiovascular Diseases; Dicarboxylic Acids; Eicosapentaenoic Acid; Ezetimibe; Fatty Acids; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; PCSK9 Inhibitors; RNA, Small Interfering | 2021 |
Unmet Need for Further LDL-C Lowering in India despite Statin Therapy: Lipid Association of India Recommendations for the Use of Bempedoic Acid.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Dicarboxylic Acids; Ezetimibe; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Proprotein Convertase 9 | 2022 |
Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Cost-Effectiveness Analysis; Ezetimibe; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Proprotein Convertase 9; Retrospective Studies; Risk Factors | 2023 |
Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Health Care Costs; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Risk Factors | 2022 |
Lipid Lowering in "Very High Risk" Patients Undergoing Coronary Artery Bypass Surgery and Its Projected Reduction in Risk for Recurrent Vascular Events: A Monte Carlo Stepwise Simulation Approach.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Bypass; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2023 |
Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction ("Jena auf Ziel").
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Proprotein Convertase 9; Prospective Studies; ST Elevation Myocardial Infarction; Treatment Outcome | 2023 |
Impact of conventional lipid-lowering therapy on circulating levels of PCSK9: protocol for a systematic review and meta-analysis of randomised controlled trials.
Topics: Adult; Bile Acids and Salts; Ezetimibe; Fatty Acids; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Meta-Analysis as Topic; Niacin; Proprotein Convertase 9; Proprotein Convertases; Review Literature as Topic; Subtilisin; Systematic Reviews as Topic | 2022 |
Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients.
Topics: Anticholesteremic Agents; Austria; Cholesterol, LDL; Ezetimibe; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2023 |